The Focus On Resistant Depression Is A Key Trend In The Antidepressants Industry

Antidepressants Market Report 2021: COVID-19 Implications And Growth To 2030

Antidepressants Global Market Report 2021: COVID-19 Implications And Growth To 2030

The Business Research Company’s Antidepressants Global Market Report 2021: COVID-19 Implications And Growth To 2030

LONDON, GREATER LONDON, UK, March 23, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

The treatment for resistant depression is a key trend in the antidepressant market. Ketamine is the new treatment that is used for anesthesia during surgery, which stimulates the development of glutamate and prompts the brain to form new neural connections. It makes the brain more adaptable and capable of developing new pathways and helps people to create more optimistic thoughts and behaviors. In 2019, Food and Drug Administration (FDA) approved a new ketamine depression drug esketamine which is one half of the ketamine compound. The drug must be administered as a nasal spray and patients must be taking another antidepressant at the same time. Also, the drugs can be prescribed to only those patients who have (unsuccessfully) tried two antidepressants before.

Other antidepressant market trends include mergers and acquisitions. In May 2018, Allergan, an Ireland based company, focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world acquired Aptinyx for an unclosed amount. Through this acquisition, Allergan gained important insights into NMDA receptor modulation as a potential therapeutic approach for depression. Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders.

Read More On The Global Antidepressants Market Report:
https://www.thebusinessresearchcompany.com/report/antidepressants-global-market-report-2020-30-covid-19-implications-and-growth

The antidepressants market covered in this report is segmented by product into selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant (TCA), monoamine oxidase inhibitor (MAOI); by drug class into monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants; by depressive disorder into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder.

The global antidepressants market is expected to decline from $26.25 billion in 2020 to $15.87 billion in 2021 at a compound annual growth rate (CAGR) of -39.5%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The antidepressant market size is expected to reach $21.28 billion in 2025 at a CAGR of 7.6%.

Major players in the antidepressants drugs market are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, and Sun Pharmaceuticals Pvt Ltd.

Antidepressants Global Market Report 2021: COVID-19 Implications And Growth To 2030 is one of a series of new reports from The Business Research Company that provides antidepressants market overview, forecast antidepressants market size and growth for the whole market, antidepressants market segments, and geographies, antidepressants market trends, antidepressants market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Antidepressants Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2881&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Neurostimulation Devices Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/neurostimulation-devices-global-market-report

Residential Substance Abuse And Mental Health Facilities Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/residential-substance-abuse-and-mental-health-facilities-global-market-report-2020-30-covid-19-implications-and-growth

Physicians And Other Health Practitioners Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/physicians-and-other-health-practitioners-global-market-report-2020-30-covid-19-impact-and-recovery

Psychologists Global Market Report 2018
https://www.thebusinessresearchcompany.com/report/psychologists-global-market-report-2018

Psychiatrists Market – By Type (Mental Disorder Type, Patient Type, Geography), Drivers, Restraints, And Major Players, By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/psychiatrists-market

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire